Market Trends of Hypogonadism Treatment Industry
This section covers the major market trends shaping the Hypogonadism Treatment Market according to our research experts:
In Treatment Type Segment, Testosterone Replacement Therapy is Expected to Witness a Healthy Growth in Future
Testosterone replacement therapy is expected to contribute the largest revenue considering the fact that hypogonadism is more prevalent in men. Several government initiatives and product approvals are also boosting the testosterone replacement therapy. For instance, Clarus Therapeutics, in May 2019, received the FDA approval for Jatenzo testosterone, an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. In addition, Antares Pharma received the FDA approval in 2018 for Xyosted (testosterone enanthate) Injection.
In addition, the decreasing rate of fertility is leading to the high chances of hypogonadism and promoting the revenue growth of the overall market
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the global hypogonadism treatment market throughout the forecast period. This dominance is mainly owing to increasing cases of hypogonadism with raising awareness about the hormonal disorder, increased adoption of newer highly advanced products and advanced healthcare infrastructure. As per the report published in the European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States witnessed an increase between 1.8 and 4-fold over the last two decades (1997 - 2017) which is resulting in the growth of hypogonadism market.
